Close
Nordic 9Nordic 9

Rosetta Capital (investor - Venture Capital)

United Kingdom rosettacapital.com
See something wrong or missing? Let us know
Offices:Letchworth Garden City

Rosetta Capital is a specialist venture capital from the UK firm focused in the life science and medical technology sectors via direct secondary transactions.

Average round investment:35.73M USD
Average number per year:1.0
Distribution: 2024 (1)2022 (1)2017 (1)2016 (1)2013 (1)
Portfolio companies: United Kingdom Mission TherapeuticsIreland Carrick TherapeuticsSweden Modus Therapeutics See the entire list
Mostly invests in: Sweden Sweden (3) Health services (5)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Rosetta Capital

Name Criteria
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Digitalis Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States SR One
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Magnetic Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mark P. Stevenson
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Revelation Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Dementia Discovery Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Top